Ex-Eylea Leader Launches Biotech Targeting Untapped Eye Market
Complement Therapeutics Exits Stealth Mode
Former Bayer executive Rafiq Hasan believes the start-up’s gene therapy candidate can open up treatment to millions of patients with dry AMD and geographic atrophy.
You may also be interested in...
Eyestem founder and CEO talks to Scrip about progress made by the firm’s experimental treatment for dry age-related macular degeneration, cell and gene therapy pricing considerations and the wider competitive landscape. The company is also developing treatments for retinitis pigmentosa and idiopathic pulmonary fibrosis.
One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.
Venture capitalists speaking at Biocom’s Global Life Science Partnering Conference looked forward to a return to rational valuations that could enable better returns for investors and pharma buyers.